Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Servier, Treventis link up in new agreement
February 2018
SHARING OPTIONS:

PARIS & TORONTO—A strategic research partnership is underway between Servier and Treventis, with the aim of targeting misfolded proteins thought to play roles in neurodegenerative diseases. The drug discovery program will look at targeting tau and amyloid-β (Aβ), a strategy that will hopefully slow the progression of Alzheimer’s disease pathology in the brain. Per the terms of the deal, the companies will co-develop the programs until the selection of a Phase 1 candidate, with Servier funding all research costs and claiming exclusive worldwide rights to develop and commercialize any selected compounds. Treventis and Servier will jointly develop compounds identified by the former’s Common Conformational Morphology technology to inhibit tau and Aβ oligomer formation. The agreement also covers the development and validation of translational biomarkers to support this work.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.